Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

por Fogelman, David, Cubillo, Antonio, García‐Alfonso, Pilar, Mirón, María Luisa Limón, Nemunaitis, John, Flora, Daniel, Borg, Christophe, Mineur, Laurent, Vieitez, Jose M., Cohn, Allen, Saylors, Gene, Assad, Albert, Switzky, Julie, Zhou, Li, Bendell, Johanna
Publicado 2018

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

por Bendell, Johanna C., Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López‐López, Carlos, García‐Alfonso, Pilar, Hussein, Maen, Miron, Maria‐Luisa Limon, Cervantes, Andrés, Montagut, Clara, Vivas, Cristina Santos, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, van der Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert
Publicado 2019